{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:55:05Z","timestamp":1785902105255,"version":"3.56.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.leukres.2023.107346","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T13:39:04Z","timestamp":1687959544000},"page":"107346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["FLAG based v\/s Standard 3\u00a0+\u00a07 induction therapy in treatment na\u00efve Acute Myeloid Leukemia: Time to think \u201cbeyond anthracyclines\u201d"],"prefix":"10.1016","volume":"132","author":[{"given":"Mohd Rizwan","family":"Shaikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhumika","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3100-558X","authenticated-orcid":false,"given":"Rohan","family":"Halder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4630-0207","authenticated-orcid":false,"given":"Reema","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Riyan","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8743-1801","authenticated-orcid":false,"given":"Narendra","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayaz","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeet Prakash","family":"Mirgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Bhurani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10147","key":"10.1016\/j.leukres.2023.107346_bib1","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.leukres.2023.107346_bib2","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"New Engl. J. Med."},{"issue":"9","key":"10.1016\/j.leukres.2023.107346_bib3","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.clml.2021.05.016","article-title":"Acute myeloid leukemia: historical perspective and progress in research and therapy over 5 decades","volume":"21","author":"Kantarjian","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"21","key":"10.1016\/j.leukres.2023.107346_bib4","doi-asserted-by":"crossref","first-page":"5285","DOI":"10.1182\/blood.V124.21.5285.5285","article-title":"FLAG-IDA has significant activity as frontline induction or salvage therapy for patients with high risk and\/or relapsed or refractory acute myeloid leukemia (AML)","volume":"124","author":"Bhella","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2023.107346_bib5","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/bjh.13406","article-title":"Acute myeloid leukaemia: challenges and real world data from India","volume":"170","author":"Philip","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"Supplement_1","key":"10.1016\/j.leukres.2023.107346_bib6","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1182\/blood-2019-127623","article-title":"Induction related mortality in acute myeloid leukemia: multivariate model of predictive score from the indian acute leukemia research database (INwARD) of the Hematology Cancer Consortium (HCC)","volume":"134","author":"Kayal","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107346_bib7","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1200\/GO.20.00240","article-title":"Infection prevalence in adolescents and adults with acute myeloid leukemia treated in an indian tertiary care center","volume":"6","author":"Jain","year":"2020","journal-title":"JCO Glob. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2023.107346_bib8","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/ajco.12333","article-title":"Long-term outcomes for patients with acute myeloid leukemia: A single-center experience from AIIMS, India: long-term outcomes for patients with AML","volume":"11","author":"Bahl","year":"2015","journal-title":"Asia Pac. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2023.107346_bib9","first-page":"46","article-title":"FLAG regimen with or without idarubicin in children with relapsed\/refractory acute leukemia: experience from a Turkish Pediatric Hematology Center","volume":"34","author":"Y\u0131lmaz Bengoa","year":"2017","journal-title":"Turk. J. Haematol. J. Turk. Soc. Haematol."},{"issue":"3","key":"10.1016\/j.leukres.2023.107346_bib10","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3346\/jkms.2009.24.3.498","article-title":"The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia","volume":"24","author":"Lee","year":"2009","journal-title":"J. Korean Med. Sci."},{"issue":"6","key":"10.1016\/j.leukres.2023.107346_bib11","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.clml.2021.01.011","article-title":"Propensity-score matched comparison of salvage chemotherapy regimens in relapsed\/refractory acute myeloid Leukemia","volume":"21","author":"Reid","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"8","key":"10.1016\/j.leukres.2023.107346_bib12","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ajh.26601","article-title":"Venetoclax combined with FLAG\u2010IDA induction and consolidation in newly diagnosed acute myeloid leukemia","volume":"97","author":"DiNardo","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2023.107346_bib13","series-title":"WHO Handbook for Reporting Results of Cancer Treatment","first-page":"45","author":"Organization","year":"1979"},{"issue":"12","key":"10.1016\/j.leukres.2023.107346_bib14","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD working party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2023.107346_bib15","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.leukres.2023.107346_bib16","unstructured":"Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy | Journal of Clinical Oncology [Internet]. [cited 2023 Jan 15]. Available from: https:\/\/ascopubs.org\/doi\/full\/10.1200\/JCO.20.00572."},{"issue":"6","key":"10.1016\/j.leukres.2023.107346_bib17","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","article-title":"Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial","volume":"9","author":"Wang","year":"2022","journal-title":"Lancet Haematol."},{"issue":"6","key":"10.1016\/j.leukres.2023.107346_bib18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/FPC.0000000000000431","article-title":"Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia","volume":"31","author":"Meg\u00edas-Vericat","year":"2021","journal-title":"Pharm. Genom."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623006112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623006112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:04:26Z","timestamp":1758935066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212623006112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":18,"alternative-id":["S0145212623006112"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107346","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FLAG based v\/s Standard 3\u00a0+\u00a07 induction therapy in treatment na\u00efve Acute Myeloid Leukemia: Time to think \u201cbeyond anthracyclines\u201d","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107346","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107346"}}